Inhibition of platelet derived growth factor receptor B (PDGFRB) with imatinib mesylate or sunitinib malate has shown some efficacy in carcinoma models (88–90) but has not yet been thoroughly evaluated in the context of lymphomas. The gene discussed is PDGFRB; the disease is lymphoma.